Calcitriol Monotherapy for X-Linked Hypophosphatemia

Status Recruiting

Clinical Trial Summary

Children and adults with XLH recruited will be treated with calcitriol alone (without phosphate supplementation) for one year, during which the calcitriol dose will be escalated during the first 3 months of therapy. The investigators hypothesize that treatment of adults and children with XLH alone will improve serum phosphate levels and skeletal mineralization without causing an increase in kidney calcifications. The study will also examine if calcitriol therapy will improve growth in children.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Familial Hypophosphatemic Rickets
Hypophosphatemia
Hypophosphatemic Rickets
Hypophosphatemic Rickets, X-Linked Dominant
Rickets
X-linked Hypophosphatemia

Clinical Trial Details

NCT number	NCT03748966
Study type	Interventional
Source	Massachusetts General Hospital
Contact	Eva S Liu, MD
Phone	16175255412
Email	esliu@bwh.harvard.edu
Status	Recruiting
Phase	Early Phase 1
Start date	March 28, 2019
Completion date	March 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02915705` - Efficacy and Safety of Burosumab (KRN23) Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)	Phase 3
Recruiting	`NCT03879915` - Dental Implants in Patients With X-linked Hypophosphatemia
Active, not recruiting	`NCT03193476` - Registry for Patients With X-Linked Hypophosphatemia
Completed	`NCT02526160` - Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)	Phase 3
Recruiting	`NCT05181839` - A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth
Completed	`NCT04146935` - Examining the Effect of Burosumab on Muscle Function	Phase 4
Completed	`NCT02750618` - Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)	Phase 2
Active, not recruiting	`NCT03745521` - Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners
Completed	`NCT03920072` - Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH	Phase 3
Recruiting	`NCT04419363` - Burosumab in Children and Adolescents With X-linked Hypophosphatemia	Phase 4
Completed	`NCT02163577` - Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)	Phase 2
Active, not recruiting	`NCT03651505` - X-linked Hypophosphatemia Disease Monitoring Program
Completed	`NCT06067932` - Foot Disorders in X-linked Hypophosphatemia
Completed	`NCT04695860` - Anti-FGF23 (Burosumab) in Adult Patients With XLH	Phase 3
Completed	`NCT02312687` - Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)	Phase 2
Completed	`NCT03596554` - X-linked Hypophosphatemia and FGF21
Recruiting	`NCT03820518` - Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia	Phase 4
Completed	`NCT01571596` - An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia	Phase 1/Phase 2
Completed	`NCT04273490` - Characterising Pain, QoL, Body Composition, Arterial Stiffness, Muscles and Bones in Adult Persons With XLH and Healthy Controls
Completed	`NCT03489993` - FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)